Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of NRXS is 6.6 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell